Document is current

Article History

Received: 15 February 2022

Accepted: 23 May 2022

First Online: 10 June 2022

Declarations

:

: The study was approved by the Comité de Protection des Personnes Ile de France VI (No. 84-14). Informed consent was obtained from patients.

: Not applicable.

: Dr. Alexandre Demoule reports personal fees from Medtronic, grants, personal fees and non-financial support from Philips, personal fees from Baxter, personal fees from Hamilton, personal fees and non-financial support from Fisher & Paykel, grants from the French Ministry of Health, personal fees from Getinge, grants and personal fees from Respinor, grants and non-financial support from Lungpacer, unrelated to the work submitted. Dr. Thomas Similowski reports, over the last 3 years, (1) personal fees from ADEP assistance, AstraZeneca France, Boehringer Ingelheim France, Chiesi France, Lungpacer Inc., Novartis France, and Vitalaire; and (2) as a member of the board of a research association, unrestricted grants from Covidien, Lungpacer, Maquet, and Philips, all unrelated to the present work. Dr. Similowski is listed as inventor on issued patents (WO2008006963A3, WO2012004534A1, WO2013164462A1) describing EEG responses to experimental and clinical dyspnea to identify and alleviate dyspnea in non-communicative patients. Dr. Côme Bureau reports personal fees from Meditor and Otsuka all unrelated to the present work. Dr. Martin Dres reports over the last three years personal fees from Lungpacer Inc., congress registration from Dräger and Research Contract with Bioserenity. Dr. Elise Morawiec, Dr. Julien Mayaux, Dr. Julie Delemazure have no competing interests related to this work.